Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» myasthenia gravis
myasthenia gravis
J&J, with adult approval in sight, posts adolescent myasthenia gravis data on $6.5B FcRn blocker
Fierce Biotech
Tue, 10/15/24 - 10:10 am
JNJ
nipocalimab
myasthenia gravis
adolescents
Amgen claims success for two immune drugs, but results underwhelm Wall Street
BioPharma Dive
Wed, 09/25/24 - 11:46 am
Amgen
rocatinlimab
atopic dermatitis
Uplizna
myasthenia gravis
Amgen's muscular disorder drug meets main goal in late-stage study
Reuters
Tue, 09/24/24 - 09:59 pm
Amgen
Uplinza
clinical trials
myasthenia gravis
J&J submits touted autoimmune disease drug for FDA approval
BioPharma Dive
Thu, 08/29/24 - 11:24 am
JNJ
myasthenia gravis
FDA
nipocalimab
J&J unwraps pivotal data on $6.5B autoimmune asset as it prepares to crash argenx and UCB's party
Fierce Biotech
Mon, 07/1/24 - 11:23 am
JNJ
nipocalimab
myasthenia gravis
clinical trials
UCB
Argenx
Argenx shrugs off myasthenia gravis threat from UCB as Vyvgart nears next potential launch
Fierce Pharma
Fri, 05/10/24 - 11:37 am
Argenx
myasthenia gravis
Vyvgart
Roche autoimmune disease drug disappoints in closely watched trial
BioPharma Dive
Thu, 03/21/24 - 06:36 pm
Roche
Chugai
clinical trials
myasthenia gravis
Enspryng
J&J’s growing rare disease focus brings a potential multi-use treatment to the table
Pharma Voice
Thu, 03/7/24 - 05:29 pm
JNJ
nipocalimab
myasthenia gravis
J&J's immune disorder drug succeeds in mid and late-stage studies
Reuters
Mon, 02/5/24 - 10:14 am
JNJ
autoimmune disease
clinical trials
nipocalimab
myasthenia gravis
Sjögren’s syndrome
Argenx's Vyvgart gains commercial momentum in gMG as company plots expansion into new uses
Fierce Pharma
Wed, 11/1/23 - 11:04 am
Argenx
Vygart
myasthenia gravis
FDA Approves UCB’s Complement Inhibitor for Generalized Myasthenia Gravis
BioSpace
Wed, 10/18/23 - 11:22 am
UCB Pharma
Zilbrysq
myasthenia gravis
UCB stakes claim to gMG market as FDA clears Rystiggo
Pharmaphorum
Tue, 06/27/23 - 11:21 am
UCB Pharma
Rystiggo
myasthenia gravis
FDA
Sanofi Admits Defeat for Myasthenia Gravis Candidate, Drops Phase III Trial
BioSpace
Fri, 02/3/23 - 10:31 am
Sanofi
tolebrutinib
myasthenia gravis
Argenx Scores Priority Review for Generalized Myasthenia Gravis Therapeutic
BioSpace
Tue, 11/22/22 - 04:30 pm
Argenx
FDA
priority reviews
myasthenia gravis
efgartigimod
Seeking sibling for Vyvgart, argenx files for FDA approval of subcutaneous efgartigimod
Fierce Pharma
Tue, 09/27/22 - 10:16 am
Argenx
Vyvgart
myasthenia gravis
efgartigimod
FDA
As Vyvgart launch gains steam, Argenx CEO says his company can achieve 'standalone' success
Fierce Pharma
Wed, 09/14/22 - 09:41 am
Argenx
Vyvgart
innovation
myasthenia gravis
FDA Partially Halts Sanofi’s BTK Inhibitor for Multiple Sclerosis, Myasthenia Gravis
Pharma Live
Thu, 06/30/22 - 10:59 am
Sanofi
multiple sclerosis
myasthenia gravis
FDA
tolebrutinib
clinical trials
clinical hold
Janssen Recruiting for Phase III Trials of Potential Myasthenia Gravis Game Changer
BioSpace
Mon, 06/20/22 - 10:57 am
Janssen
JNJ
clinical trials
nipocalimab
myasthenia gravis
AstraZeneca's Ultomiris scores its 3rd FDA approval, setting up market clash with argenx
Fierce Pharma
Thu, 04/28/22 - 11:05 am
AstraZeneca
Ultomiris
FDA
myasthenia gravis
Argenx takes a step towards convenience
EP Vantage
Wed, 03/23/22 - 10:27 am
Argenx
efgartigimod
Vyvgart
myasthenia gravis
Pages
1
2
next ›
last »